Updates in the molecular pathology of non-small cell lung cancer

Lung cancer in never smokers: The role of different risk factors other than tobacco smoking

(2020) Luis Corrales et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Primary Mammary-Analogue Secretory Carcinoma of the Lung: A Rare Entity With an Unusual Location

(2020) Josean Ramos et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Identification of CTNNB1-PLAG1 gene rearrangement in a patient with pulmonary pleomorphic adenoma

(2020) Miki Asahina et al.   VIRCHOWS ARCHIV

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

(2020) Diana M Merino et al.   Journal for ImmunoTherapy of Cancer

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer

(2020) Yuxin Mu et al.   Frontiers in Oncology

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

(2020) Wanyuan Cui et al.   LUNG CANCER

Pulmonary epithelial–myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report

(2020) Naoki Yanagawa et al.   Diagnostic Pathology

Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

(2020) Timothy F. Burns et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review

(2019) Kengo Takeuchi   Frontiers in Physiology

Genomic correlates of response to immune checkpoint blockade

(2019) Tanya E. Keenan et al.   NATURE MEDICINE

Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum

(2019) Makoto Urano et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy

(2019) Susan J. Hsiao et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing

(2019) Jianming Pei et al.   MODERN PATHOLOGY

Direct Ras G12C inhibitors: crossing the rubicon

(2019) Colin R. Lindsay et al.   BRITISH JOURNAL OF CANCER

Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms

(2019) James P. Solomon et al.   CANCER RESEARCH

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

(2019) Robin Guo et al.   Journal of Thoracic Oncology

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer

(2019) Derek Wong et al.   PATHOLOGY & ONCOLOGY RESEARCH

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

(2019) Miriam Molina-Arcas et al.   Science Translational Medicine

Identifying patients with NTRK fusion cancer

(2019) J P Solomon et al.   ANNALS OF ONCOLOGY

Thoracic SMARCA4-deficient sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas

(2019) N. Rekhtman et al.   Journal of Thoracic Oncology

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

(2019) Sylvie Lantuejoul et al.   Journal of Thoracic Oncology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

(2018) Neal I. Lindeman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Primary mammary analogue secretory carcinoma of the lung: a case report

(2018) Tao Huang et al.   HUMAN PATHOLOGY

Hyalinizing clear cell carcinoma of the bronchial glands: presentation of three cases and pathological comparisons with salivary gland counterparts and bronchial mucoepidermoid carcinomas

(2018) Manabu Takamatsu et al.   MODERN PATHOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

(2018) Chee Khoon Lee et al.   JAMA Oncology

Molecular characterization of cancers with NTRK gene fusions

(2018) Zoran Gatalica et al.   MODERN PATHOLOGY

SMARCA4-deficient Thoracic Sarcomas

(2018) Raul Perret et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Diagnosis of NUT carcinoma of lung origin by next-generation sequencing: case report and review of the literature

(2018) Naiquan Mao et al.   CANCER BIOLOGY & THERAPY

NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment

(2018) Christopher A. French   PATHOLOGY INTERNATIONAL

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

(2017) Alexander Drilon et al.   Journal of Thoracic Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer

(2017) Guanghui Cui et al.   MEDICINE

Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities

(2017) Akihiko Yoshida et al.   MODERN PATHOLOGY

SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior

(2017) Jennifer L Sauter et al.   MODERN PATHOLOGY

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance

(2017) Alison M. Schram et al.   Nature Reviews Clinical Oncology

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ectopic protein interactions within BRD4–chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma

(2017) Artyom A. Alekseyenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature

(2017) Alireza Salem et al.   VIRCHOWS ARCHIV

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Primary Pulmonary Salivary Gland-type Tumors

(2016) Nadja Falk et al.   ADVANCES IN ANATOMIC PATHOLOGY

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations

(2016) Claire Tissot et al.   LUNG CANCER

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Immunotherapy for Gastroesophageal Cancer

(2016) Emily Goode et al.   Journal of Clinical Medicine

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

(2015) Y. Mitani et al.   CLINICAL CANCER RESEARCH

The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains

(2015) Artyom A. Alekseyenko et al.   GENES & DEVELOPMENT

An uncommon primary lung tumour: hyalinizing clear cell carcinoma, salivary gland-type

(2015) Akeesha A Shah et al.   HISTOPATHOLOGY

Primary pulmonary hyalinizing clear cell carcinoma of bronchial submucosal gland origin

(2015) Joaquín J. García et al.   HUMAN PATHOLOGY

Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma

(2015) Anja C. Roden et al.   Journal of Thoracic Oncology

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

(2015) Francois Le Loarer et al.   NATURE GENETICS

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma

(2015) K. J. Brayer et al.   Cancer Discovery

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

(2015) Helena A. Yu et al.   JAMA Oncology

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis

(2014) K Tsuta et al.   BRITISH JOURNAL OF CANCER

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Histopathologic, immunophenotypic and cytogenetic features of pulmonary mucoepidermoid carcinoma

(2014) Anja C Roden et al.   MODERN PATHOLOGY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clear Cell Odontogenic Carcinomas Show EWSR1 Rearrangements

(2013) Elizabeth A. Bilodeau et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

EWSR1 Genetic Rearrangements in Salivary Gland Tumors

(2013) Akeesha A. Shah et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

KIF5B-RETfusions in Chinese patients with non-small cell lung cancer

(2013) Weijing Cai et al.   CANCER

Molecular Pathways: ROS1 Fusion Proteins in Cancer

(2013) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

MET As a Possible Target for Non–Small-Cell Lung Cancer

(2013) Ahad A. Sadiq et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma

(2013) Po Yee Yip et al.   Journal of Thoracic Oncology

Genetic alterations defining NSCLC subtypes and their therapeutic implications

(2013) Larissa A. Pikor et al.   LUNG CANCER

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

(2013) J. F. Gainor et al.   ONCOLOGIST

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

(2012) Ramaswamy Govindan et al.   CELL

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

MAP kinase signalling cascades and transcriptional regulation

(2012) Shen-Hsi Yang et al.   GENE

The transcriptional landscape and mutational profile of lung adenocarcinoma

(2012) J.-S. Seo et al.   GENOME RESEARCH

RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

(2012) Rui Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland

(2011) Cristina R. Antonescu et al.   GENES CHROMOSOMES & CANCER

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms

(2011) Louis B Brill et al.   MODERN PATHOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity

(2010) Alena Skálová et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

MYB Expression and Translocation in Adenoid Cystic Carcinomas and Other Salivary Gland Tumors With Clinicopathologic Correlation

(2010) Robert B. West et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains

(2010) Nicolas Reynoird et al.   EMBO JOURNAL

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody

(2009) Herbert Haack et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma

(2009) Rosane De Oliveira Duarte Achcar et al.   HUMAN PATHOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology